How GLP-1 Titration Schedules Work

Disclosure: Dose Digest is an educational publisher. We may have a financial affiliation with some entities featured on this page. This article is educational only and is not medical advice.

The short answer: GLP-1 prescribing information describes a gradual increase in stages, at set intervals, from a starting dosage toward a maintenance dosage. The labels give tolerability, especially fewer gastrointestinal reactions, as the reason. They also tell clinicians to consider response and tolerability, and to consider delaying escalation or choosing a lower maintenance dosage. Your clinician determines the pace.

What is titration, and why do GLP-1 labels use it?

Titration means adjusting a medicine in steps instead of starting at the eventual target. The GLP-1 and GIP/GLP-1 labels we reviewed all use the same basic shape: begin at an initiation dosage, move up in stages, then settle at a maintenance dosage.

The stated reason is tolerability. The Wegovy label says to follow its escalation “to reduce the risk of gastrointestinal adverse reactions.” The Ozempic, Mounjaro and Zepbound labels use the same phrase.

This guide describes structure only. It leaves out amounts and intervals on purpose. Those details differ by product and indication, and the labels are written for prescribers.

How do the semaglutide labels describe the step-up?

As of Sept. 30, 2026, the current Wegovy label (revised 06/2026) covers both the injection and the tablets. For the injection, it describes an initiation dosage followed by escalation at fixed intervals until a maintenance dosage is reached. The tablets have their own escalation structure, taken daily rather than weekly.

The Ozempic label (revised 05/2026) ties later increases to the clinical goal. It says a higher dosage may be used if additional glycemic control is needed, after a minimum time on the current one. It also names a separate maintenance pathway for people with type 2 diabetes and chronic kidney disease.

And the tirzepatide labels?

The Zepbound label (revised 08/2026) states that its initiation dosage is “not approved as a maintenance dosage.” After that, the label describes increases in fixed increments, each after a minimum time on the current dose, until a maintenance dosage is reached. Maintenance options differ by indication: the label lists one set for weight reduction and another for obstructive sleep apnea.

The Mounjaro label (revised 08/2026) also starts low and increases in fixed increments “if additional glycemic control is needed.” It sets a lower ceiling for pediatric patients than for adults.

Who sets the pace?

The labels are addressed to prescribers, and the wording is permissive. The Wegovy and Zepbound labels both say to “consider treatment response and tolerability” when selecting the maintenance dosage. Ozempic and Mounjaro make further increases conditional on whether more glycemic control is needed.

So the label describes a structure. It does not hand a reader a timetable. Your clinician determines the pace and the destination for you, based on your history, your response and how you tolerate each stage.

What does the label say about holding at a dose?

The labels include explicit language about slowing down or stopping at a step:

Wegovy tablets: “If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation.” The Wegovy injection label describes delaying escalation if a step is not tolerated.
Zepbound: “If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.”

The Wegovy tablet and Zepbound statements above are options for the prescriber, not rules for the patient. Separately, in the label’s cardiovascular outcomes trial, patients who could not tolerate the recommended escalation “could stay at a lower dose level.” That line describes what happened in the trial, not a recommendation.

Why is the escalation period watched closely?

Gastrointestinal reactions. The labels’ trial populations, designs and definitions of gastrointestinal reactions differ, and these rates cannot be compared across drugs. In the Wegovy label’s weight-reduction trials in adults, 73% of injection-treated patients and 47% of placebo patients reported gastrointestinal reactions; the label says these were most frequently reported during dosage escalation. Separately, in the Zepbound label’s two pooled weight-reduction trials (2,519 treated adults, up to 72 weeks), gastrointestinal reactions were reported by 56% of treated patients in each dose arm and 30% on placebo; the label says most nausea, vomiting and diarrhea events occurred during escalation and decreased over time.

Kidney function. The Wegovy, Ozempic, Zepbound and Mounjaro labels all say to monitor renal function in patients who report reactions that could cause dehydration, “especially during dosage initiation and escalation.”

Gastric emptying and oral contraceptives. The Zepbound and Mounjaro labels say the delay in gastric emptying is largest after the first dose and diminishes over time. The labels include guidance on oral hormonal contraceptives around initiation and escalation; ask your prescriber.

What did one trial show about people on lower doses?

In the Wegovy label’s cardiovascular outcomes trial (NCT03574597), 17,604 adults aged 45 or older, with established cardiovascular disease and overweight or obesity but without diabetes, were followed for a median of 41.8 months. Of those still on treatment at one year, 76% were on the labeled target dose, 8% on the next-lower labeled dose and 16% on lower doses still. At two years the figures were 77%, 7% and 17%.

These are in-trial figures. They show that dosing in a large trial did not always reach the target. They are not a benchmark for any individual.

How do the labels differ from product to product?

Injections are labeled for once-weekly use and the tablets for once-daily use. Each label sets its own staging, its own maintenance options and its own missed-dose language, and indications shape what each one says. Moving between products or forms is a prescriber decision, and the Wegovy label has a section on switching between its injection and tablets. This article gives no switching guidance.

Questions a reader might bring to their own clinician

Which product and form is being considered, and what does its label say about escalation?
What will we watch for during each stage, and whom do I contact if something changes?
Under what circumstances would we pause escalation, or choose a lower maintenance dosage?
How do my other medicines, including oral contraceptives, fit with the escalation period?
What should I do about a missed dose on this product?

Frequently asked questions

Is titration the same for every GLP-1 medicine?

No. Each label describes its own structure. Injections and tablets differ, and so do the products and indications.

Do the labels say everyone must move up on a fixed timeline?

The labels describe a usual structure. They also say clinicians may consider delaying escalation or choosing a lower maintenance dosage when a dose is not tolerated.

Why do the labels start at a lower dosage?

The labels say the escalation is meant to reduce the risk of gastrointestinal adverse reactions.

Will I find my dosing schedule in this article?

No, by design. Your prescriber’s instructions, your product’s label and its Medication Guide are the places to look.

Where can I read the labels myself?

The FDA label PDFs are linked in the text and listed under Sources.